Medicare Just Rewired Breakthrough-Device Coverage — What RAPID Means for Diligence

← Back to All Insights

Between April and August 2026, CMS and FDA changed how a breakthrough medical device reaches Medicare coverage and payment. The FY 2027 inpatient final rule, released July 31, 2026, settled the payment piece; the RAPID notice published August 11 is open for comment until October 13. Together they split the device world in two.

For anyone underwriting a medtech investment or acquisition, this is not a footnote. Reimbursement can undo a clean regulatory story, and the rules governing it just moved.

What changed

Three moves, close together:

• RAPID (announced April 23, 2026; proposed in a notice with comment period on August 11). The Regulatory Alignment for Predictable and Immediate Device pathway aligns FDA and CMS earlier in development. For eligible Breakthrough Devices (Class III, or Class II in FDA's TAP program) that address an unmet need among Medicare beneficiaries, CMS would issue a proposed national coverage determination the same day FDA authorizes the device, with national coverage possible as soon as about two months after authorization, compared with a year or more on the current path.
• The NTAP "alternative pathway" is being repealed. Breakthrough Devices have been able to qualify for a new-technology add-on payment without separately demonstrating substantial clinical improvement. The FY 2027 inpatient final rule (released July 31, 2026) ends that shortcut for applications beginning in FY 2028; devices designated Breakthrough by September 30, 2026 can still apply through it for FY 2028 and FY 2029.
• TCET is paused. As of the August 11, 2026 notice, CMS has stopped taking new candidates into the Transitional Coverage for Emerging Technologies pathway while it stands RAPID up.

Why it matters for diligence

Read the three moves together and reimbursement risk has bifurcated. A device that carries — or can realistically earn — FDA Breakthrough Device designation, and that addresses a Medicare-relevant unmet need, would have a fast, unusually predictable on-ramp to national coverage: the time from authorization to Medicare coverage could shrink from a year or more to a couple of months.

Everything else moved the other way. With TCET paused and the NTAP shortcut closed to new applications from FY 2028, a device without that designation faces the longer, evidence-heavy road — and now has to prove substantial clinical improvement to earn the add-on payment it might previously have received more easily. The gap between the two lanes is wider than it was a year ago.

"Is this device RAPID-eligible?" has moved from a footnote in the reimbursement section to a first-order question about time-to-revenue.

What to actually check

• Does the device hold FDA Breakthrough Device designation — or is there a credible, documented basis to expect it?
• Does it address an unmet need in a Medicare population, the frame RAPID is built around?
• Is there an evidence-generation plan that can support "substantial clinical improvement," now that the NTAP alternative pathway is ending (unless the device was designated Breakthrough by September 30, 2026)?
• Does the deal case assume RAPID timing, and is the device actually eligible? RAPID is still a proposal, and the agencies describe coverage as soon as about two months after authorization, compared with a year or more today.

None of this is a bet on any single coverage decision. It is a read on timeline and eligibility risk — which lane a company is in, how defensible that position is, and what it does to the revenue curve. That is the reimbursement question the RAPID era makes unavoidable.

In a Vantage report, the reimbursement domain is read from public CMS and FDA sources and cited, including a target's Breakthrough designation and RAPID eligibility as the rules stand when the report is written. Nothing here is legal or regulatory advice.